Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

BACKGROUND: One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great clinical significance....

Descripción completa

Detalles Bibliográficos
Autores principales: Bjerrum, Jacob Tveiten, Steenholdt, Casper, Ainsworth, Mark, Nielsen, Ole Haagen, Reed, Michelle AC, Atkins, Karen, Günther, Ulrich Leonhard, Hao, Fuhua, Wang, Yulan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641999/
https://www.ncbi.nlm.nih.gov/pubmed/29032767
http://dx.doi.org/10.1186/s12916-017-0949-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641999/
https://www.ncbi.nlm.nih.gov/pubmed/29032767
http://dx.doi.org/10.1186/s12916-017-0949-7

Ejemplares similares